Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-label, Single Arm Study of Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma
Conditions
Interventions
HAIC
Lenvatinib plus cadonilimab
Locations
1
China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Start Date
December 7, 2023
Primary Completion Date
December 31, 2025
Completion Date
June 30, 2027
Last Updated
December 12, 2024
NCT06707233
NCT05911633
NCT06561399
NCT04224636
NCT06397222
NCT05901194
Lead Sponsor
Tongji Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions